In an international cross-sectional registry study, classic diagnostic features of familial hypercholesterolemia were uncommon in individuals aged <18 years, and the diagnosis therefore relied on LDL-c levels or genetic confirmation. Most participants were not on lipid-lowering therapy.
AHA 2023 "This is such a fascinating time in lipid therapeutics," says Karol Watson. She substantiates this by summarizing three late-breaking science studies with VERVE-101, lepodisiran and recaticimab.
In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.
ESC Congress 2023 Stephen Nicholls shares the results of the total events analysis of the CLEAR Outcomes trial. He compares the hazard ratios of the first event and total events analyses and explains the implications of these results.
Maciej Banach presents the results of a subanalysis of the ODYSSEY APPRISE study. In this analysis differences in physicans’ behavior and factors influencing the intensity of PCSK9i therapy with alirocumab were determined in Central and Eastern Europe vs. other European countries plus Canada.
EAS Congress 2023 Florian Kronenberg discusses the EAS consensus statement on Lp(a) in ASCVD and aortic stenosis, which contains recommendations for testing of Lp(a), risk estimation, and management of patients with elevated Lp(a) levels.
A secondary analysis of the FOURIER-OLE trial investigated what the optimal achieved LDL-c levels are with PCSK9i in patients with ASCVD, with regards to long-term cardiovascular and safety outcomes.
In 2019, the ESC/EAS recommended more stringent LDL-c goals, and a greater use of combination therapies. In the SANTORINI study was investigated whether the treatment landscape has improved since then.
In an age-stratified post-hoc analysis of the RACING trial, combination therapy with a moderate-intensity statin plus ezetimibe showed similar CV benefits as high-intensity statin monotherapy in elderly ASCVD patients, regardless of age group.
In the single-arm ARCHITECT study, the authors demonstrated that the addition of alirocumab to statin therapy in asymptomatic patients with FH reduces coronary plaque burden and promotes plaque stabilization.
In a Dutch, real-world study of patients at very high CVD risk on maximum-tolerated lipid-lowering therapy, PCSK9 antibodies resulted in less relative LDL-c reduction at 6 months in women compared with men. Of note, women did have higher baseline LDL-c levels.
A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.